RESPONSE TO RUXOLITINIB IN PATIENTS WITH INTERMEDIATE-1, INTERMEDIATE-2 AND HIGH-RISK MYELOFIBROSIS: RESULTS OF THE UK ROBUST TRIAL

被引：0

作者：

Mead, A. ^{[1
]}

Clark, R. ^{[2
]}

Chacko, J. ^{[3
]}

Knapper, S. ^{[4
]}

Yin, J. ^{[5
]}

Milojkovic, D. ^{[6
]}

Farquharson, M. ^{[7
]}

Ali, S. ^{[8
]}

Garg, M. ^{[9
]}

Andrews, C. ^{[10
]}

Dawson, M. Ktiouet ^{[10
]}

Harrison, C. ^{[11
]}

机构：

[1] Univ Oxford, Weatherall Inst Mol Med, MRC, Oxford, England

[2] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool, Merseyside, England

[3] Royal Bournemouth & Christchurch Hosp NHS Fdn Tru, Bournemouth, Dorset, England

[4] Cardiff Univ, Dept Haematol, Cardiff CF10 3AX, S Glam, Wales

[5] Manchester Royal Infirm, Dept Haematol, Manchester M13 9WL, Lancs, England

[6] Hammersmith Hosp, Imperial Coll Healthcare NHS Trust, London, England

[7] Western Gen Hosp, Dept Haematol, Edinburgh EH4 2XU, Midlothian, Scotland

[8] Hull & East Yorkshire Hosp NHS Trust, Kingston Upon Hull, N Humberside, England

[9] Leicester Royal Infirm, Leicester, Leics, England

[10] Novartis Pharmaceut UK, Frimley, Camberley, England

[11] Guys & St Thomas Natl Hlth Serv Fdn Trust, London, England

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P414

引用

页码：131 / 132

页数：2

共 50 条

[31] Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial
Pardanani, Animesh
Tefferi, Ayalew
Masszi, Tamas
Mishchenko, Elena
Drummond, Mark W.
Jourdan, Eric
Vannucchi, Alessandro M.
Jurgutis, Mindaugas
Ribrag, Vincent
Rambaldi, Alessandro
Koh, Liang Piu
Rose, Shelonitda
Zhang, Jun
Harrison, Claire
[J]. BLOOD, 2020, 136
[32] BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study
Lavie, David
Ribrag, Vincent
Loschi, Michael
Yannakou, Costas K.
Alwan, Maan
Abulafia, Adi Schacham
Hernandez-Rivas, Jesus Maria
Volchek, Yulia
Fong, Chun Yew
Bonifacio, Massimiliano
Kiladjian, Jean-Jacques
Ianotto, Jean-Christophe
Garcia Gutierrez, Valentin
Tucci, Alessandra
Xicoy, Blanca
Al-Ali, Haifa Kathrin
Talpaz, Moshe
Gerber, Jonathan M.
Raman, Indu
Tomuleasa, Ciprian
Lee-Hoeflich, Si Tuen
Das, Sharmila
Wu, Bin
Zhao, Qian
Kim, Eunhee
Esposito, Oriana
Liu, Yu
Nikolova, Zariana
Tehlirian, Christopher
Coker, Shodeinde
Ayala, Rosa
[J]. BLOOD, 2023, 142
[33] UPDATED RESULTS FROM A RANDOMIZED PHASE 2 DOSE-RANGING STUDY OF THE JAK2-SELECTIVE INHIBITOR SAR302503 IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS (MF)
Talpaz, M.
Jamieson, C.
Gabrail, N.
Lebedinsky, C.
Gao, G.
Patki, A.
Lui, F.
Tefferi, A.
Pardanani, A.
[J]. HAEMATOLOGICA, 2013, 98 : 458 - 458
[34] Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels
Mascarenhas, John
Komrokji, Rami S.
Cavo, Michele
Martino, Bruno
Niederwieser, Dietger
Reiter, Andreas
Scott, Bart L.
Baer, Maria R.
Hoffman, Ronald
Odenike, Olatoyosi
Bussolari, Jacqueline
Zhu, Eugene
Huang, Fei
Rose, Esther
Sherman, Laurie
Dougherty, Souria
Feller, Faye M.
Kiladjian, Jean-Jacques
[J]. BLOOD, 2018, 132
[35] BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study
Ayala, Rosa
Lopez, Nieves
Abulafia, Adi Shacham
Alwan, Maan
Yannakou, Costas K.
Raman, Indu
Ribrag, Vincent
Fong, Chun Yew
Volchek, Yulia
Bonifacio, Massimiliano
Tucci, Alessandra
Kiladjian, Jean-Jacques
Chang, Henry
Das, Sharmila
Wu, Bin
Ravindran, Palanikumar
Shan, Vivian
Wang, Guan
Esposito, Oriana
Liu, Yu
Nikolova, Zariana
Tehlirian, Christopher
Coker, Shodeinde
Lavie, David
[J]. BLOOD, 2022, 140 : 9665 - 9667
[36] Imetelstat Is Effective Treatment for Patients With Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels
不详
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 14 - 15
[37] Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis
Pemmaraju, Naveen
Gupta, Vikas
Ali, Haris
Yacoub, Abdulraheem
Wang, Eunice S.
Lee, Sangmin
Schiller, Gary J.
Sardone, Megan
Wysowskyj, Halyna
Chen, Janice
Brooks, Christopher
Poradosu, Enrique
McDonald, Peter
Rupprecht, Nicole
Pardanani, Animesh
Tefferi, Ayalew
Talpaz, Moshe
Taparia, Minakshi S.
Verstovsek, Srdan
Khoury, Joseph D.
Patnaik, Mrinal M.
[J]. BLOOD, 2019, 134
[38] Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score
Gowin, Krisstina L.
Ballen, Karen K.
Ahn, Kwang Woo
Hu, Zhen-Huan
Liu, Ying
Masarova, Lucia
Verstovsek, Srdan
Coakley, Maria
Jain, Tania
Kuykendall, Andrew
Komrokji, Rami
Wadleigh, Martha
Patches, Sarah
Arcasoy, Murat
Green, Michael
Kandarpa, Malathi
Talpaz, Moshe
Ali, Haris
Gupta, Vikas
Devlin, Rebecca
Michaelis, Laura C.
Hobbs, Gabriela S.
Stein, Brady Lee
Pariser, Ashley
Gerds, Aaron T.
Kuber, Kierstin
Rampal, Raajit
Alyea, Edwin P., III
Popat, Uday
Sobecks, Ronald
Scott, Bart L.
Mesa, Ruben
Saber, Wael
[J]. BLOOD, 2018, 132
[39] Flow Cytometric Score Correlates with Clinical Response to Azacitidine In Intermediate-2 and High Risk Myelodysplastic Syndrome Patients
Alhan, Canan
Westers, Theresia M.
Eeltink, Corien
Cali, Claudia
Ossenkoppele, Gert J.
Van de Loosdrecht, Arjan A.
[J]. BLOOD, 2010, 116 (21) : 198 - 198
[40] The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase OAK) inhibitor: A phase 2, randomized study.
Tefferi, Ayalew
Gangat, Naseema
Niederwieser, Dietger
Van Droogenbroeck, Jan
Baer, Maria R.
Kiladjian, Jean-Jacques
Hoffman, Ronald
Finazzi, Guido
Cervantes, Francisco
Gotlib, Jason R.
Sirhan, Shireen
Apperley, Jane
Langlois, Angelique
Wan, Ying
Sherman, Laurie Jill
Dougherty, Souria
Feller, Faye
Odenike, Olatoyosi
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →